Oral immunotherapy using partially hydrolyzed formula for cow's milk protein allergy: A randomized, controlled trial

Chisato Inuo, Kenichi Tanaka, Satoko Suzuki, Yoichi Nakajima, Kazuo Yamawaki, Ikuya Tsuge, Atsuo Urisu, Yasuto Kondo

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Partially hydrolyzed cow's milk protein-based formula (pHF) possesses low allergenicity. Here, we investigate the safety and efficacy of oral immunotherapy using pHF for children with cow's milk protein allergy (CMPA). Objectives: A randomized, double-blind, controlled single-center trial was conducted to evaluate the efficacy and safety of pHF oral immunotherapy in children with CMPA. Methods: Participants were randomized into double-blind pHF-pHF and extensively hydrolyzed cow's milk protein-based formula (eHF)-pHF groups. During this phase, the pHF-pHF group received pHF and the eHF-pHF group received eHF. During the open phase, all participants received pHF. The primary end point was a change in thresholds between baseline and the end of the first phase. Secondary end points were changes in thresholds between baseline and the end of the second phase, and casein-specific immunoglobulin (Ig)E, IgG4, and basophil activation. Results: Twenty-five children, aged 1-9 years, were randomized into pHF-pHF and eHF-pHF groups. The threshold between baseline and the end of the first phase was significantly elevated in the pHF-pHF group (p = 0.048), but not in the eHF-pHF group. The threshold between other phases did not change significantly in either group. There were significant decreases in casein-specific IgE antibody levels between baseline and the second phase in the eHF-pHF group (p = 0.014). No participants suffered systemic allergic reactions requiring adrenaline or systemic corticosteroids after receiving the formulas. Conclusions: The results of this trial suggest that, in children with CMPA, tolerance to cow's milk might be safely enhanced by intake of pHF, relative to that of eHF.

Original languageEnglish
Pages (from-to)259-268
Number of pages10
JournalInternational Archives of Allergy and Immunology
Volume177
Issue number3
DOIs
Publication statusPublished - 01-10-2018

Fingerprint

Milk Hypersensitivity
Milk Proteins
Immunotherapy
Randomized Controlled Trials
Caseins
Immunoglobulin E
Safety
Basophils
Epinephrine
Adrenal Cortex Hormones
Hypersensitivity
Milk
Immunoglobulin G
Antibodies

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this

Inuo, Chisato ; Tanaka, Kenichi ; Suzuki, Satoko ; Nakajima, Yoichi ; Yamawaki, Kazuo ; Tsuge, Ikuya ; Urisu, Atsuo ; Kondo, Yasuto. / Oral immunotherapy using partially hydrolyzed formula for cow's milk protein allergy : A randomized, controlled trial. In: International Archives of Allergy and Immunology. 2018 ; Vol. 177, No. 3. pp. 259-268.
@article{5560b73b65bf4924b76ec5737ac9841d,
title = "Oral immunotherapy using partially hydrolyzed formula for cow's milk protein allergy: A randomized, controlled trial",
abstract = "Background: Partially hydrolyzed cow's milk protein-based formula (pHF) possesses low allergenicity. Here, we investigate the safety and efficacy of oral immunotherapy using pHF for children with cow's milk protein allergy (CMPA). Objectives: A randomized, double-blind, controlled single-center trial was conducted to evaluate the efficacy and safety of pHF oral immunotherapy in children with CMPA. Methods: Participants were randomized into double-blind pHF-pHF and extensively hydrolyzed cow's milk protein-based formula (eHF)-pHF groups. During this phase, the pHF-pHF group received pHF and the eHF-pHF group received eHF. During the open phase, all participants received pHF. The primary end point was a change in thresholds between baseline and the end of the first phase. Secondary end points were changes in thresholds between baseline and the end of the second phase, and casein-specific immunoglobulin (Ig)E, IgG4, and basophil activation. Results: Twenty-five children, aged 1-9 years, were randomized into pHF-pHF and eHF-pHF groups. The threshold between baseline and the end of the first phase was significantly elevated in the pHF-pHF group (p = 0.048), but not in the eHF-pHF group. The threshold between other phases did not change significantly in either group. There were significant decreases in casein-specific IgE antibody levels between baseline and the second phase in the eHF-pHF group (p = 0.014). No participants suffered systemic allergic reactions requiring adrenaline or systemic corticosteroids after receiving the formulas. Conclusions: The results of this trial suggest that, in children with CMPA, tolerance to cow's milk might be safely enhanced by intake of pHF, relative to that of eHF.",
author = "Chisato Inuo and Kenichi Tanaka and Satoko Suzuki and Yoichi Nakajima and Kazuo Yamawaki and Ikuya Tsuge and Atsuo Urisu and Yasuto Kondo",
year = "2018",
month = "10",
day = "1",
doi = "10.1159/000490804",
language = "English",
volume = "177",
pages = "259--268",
journal = "International Archives of Allergy and Immunology",
issn = "1018-2438",
publisher = "S. Karger AG",
number = "3",

}

Oral immunotherapy using partially hydrolyzed formula for cow's milk protein allergy : A randomized, controlled trial. / Inuo, Chisato; Tanaka, Kenichi; Suzuki, Satoko; Nakajima, Yoichi; Yamawaki, Kazuo; Tsuge, Ikuya; Urisu, Atsuo; Kondo, Yasuto.

In: International Archives of Allergy and Immunology, Vol. 177, No. 3, 01.10.2018, p. 259-268.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Oral immunotherapy using partially hydrolyzed formula for cow's milk protein allergy

T2 - A randomized, controlled trial

AU - Inuo, Chisato

AU - Tanaka, Kenichi

AU - Suzuki, Satoko

AU - Nakajima, Yoichi

AU - Yamawaki, Kazuo

AU - Tsuge, Ikuya

AU - Urisu, Atsuo

AU - Kondo, Yasuto

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Background: Partially hydrolyzed cow's milk protein-based formula (pHF) possesses low allergenicity. Here, we investigate the safety and efficacy of oral immunotherapy using pHF for children with cow's milk protein allergy (CMPA). Objectives: A randomized, double-blind, controlled single-center trial was conducted to evaluate the efficacy and safety of pHF oral immunotherapy in children with CMPA. Methods: Participants were randomized into double-blind pHF-pHF and extensively hydrolyzed cow's milk protein-based formula (eHF)-pHF groups. During this phase, the pHF-pHF group received pHF and the eHF-pHF group received eHF. During the open phase, all participants received pHF. The primary end point was a change in thresholds between baseline and the end of the first phase. Secondary end points were changes in thresholds between baseline and the end of the second phase, and casein-specific immunoglobulin (Ig)E, IgG4, and basophil activation. Results: Twenty-five children, aged 1-9 years, were randomized into pHF-pHF and eHF-pHF groups. The threshold between baseline and the end of the first phase was significantly elevated in the pHF-pHF group (p = 0.048), but not in the eHF-pHF group. The threshold between other phases did not change significantly in either group. There were significant decreases in casein-specific IgE antibody levels between baseline and the second phase in the eHF-pHF group (p = 0.014). No participants suffered systemic allergic reactions requiring adrenaline or systemic corticosteroids after receiving the formulas. Conclusions: The results of this trial suggest that, in children with CMPA, tolerance to cow's milk might be safely enhanced by intake of pHF, relative to that of eHF.

AB - Background: Partially hydrolyzed cow's milk protein-based formula (pHF) possesses low allergenicity. Here, we investigate the safety and efficacy of oral immunotherapy using pHF for children with cow's milk protein allergy (CMPA). Objectives: A randomized, double-blind, controlled single-center trial was conducted to evaluate the efficacy and safety of pHF oral immunotherapy in children with CMPA. Methods: Participants were randomized into double-blind pHF-pHF and extensively hydrolyzed cow's milk protein-based formula (eHF)-pHF groups. During this phase, the pHF-pHF group received pHF and the eHF-pHF group received eHF. During the open phase, all participants received pHF. The primary end point was a change in thresholds between baseline and the end of the first phase. Secondary end points were changes in thresholds between baseline and the end of the second phase, and casein-specific immunoglobulin (Ig)E, IgG4, and basophil activation. Results: Twenty-five children, aged 1-9 years, were randomized into pHF-pHF and eHF-pHF groups. The threshold between baseline and the end of the first phase was significantly elevated in the pHF-pHF group (p = 0.048), but not in the eHF-pHF group. The threshold between other phases did not change significantly in either group. There were significant decreases in casein-specific IgE antibody levels between baseline and the second phase in the eHF-pHF group (p = 0.014). No participants suffered systemic allergic reactions requiring adrenaline or systemic corticosteroids after receiving the formulas. Conclusions: The results of this trial suggest that, in children with CMPA, tolerance to cow's milk might be safely enhanced by intake of pHF, relative to that of eHF.

UR - http://www.scopus.com/inward/record.url?scp=85052750886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052750886&partnerID=8YFLogxK

U2 - 10.1159/000490804

DO - 10.1159/000490804

M3 - Article

C2 - 30134240

AN - SCOPUS:85052750886

VL - 177

SP - 259

EP - 268

JO - International Archives of Allergy and Immunology

JF - International Archives of Allergy and Immunology

SN - 1018-2438

IS - 3

ER -